Sunakiment vs WIN378
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
Sunakiment
Developed by AstraZeneca and partners
NCT06529419 · Phase 2 · completed
The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
Reported efficacy
Part A and Part B: Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)); Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Terminal rate constant (λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)): Primary outcome, adverse events in Part A (healthy adults) and Part B (asthma): acceptable safety profile, low incidence of treatment-induced antidrug antibodies (part A n=1; part B n=2); safety outcome, no formal efficacy test. The other registered primaries are pharmacokinetic. Secondary outcome, FeNO change vs placebo at day 28 in Part B: 23% reduction with 8 mg (P=.037). (not_applicable)
Result source: NCT05110976
WIN378
Developed by Windward Bio and partners
NCT05790694 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse events" (with 6 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: October 2028 · NCT07120503 (registry estimate)
Reported efficacy
Adverse events (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-AUC0-last (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Tmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Cmax (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-CL/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-Vd/F (Strat of Treatment to end of study (approsimately 160days)); Pharmacokinetics-T1/2 (Strat of Treatment to end of study (approsimately 160days)): In 50 healthy adults given single doses of 20, 60, 200, 600 or 900 mg (eight on drug and two on placebo at each level), treatment-emergent adverse events were comparable between dose groups and placebo, with no trend for increasing risk with dose escalation. Anti-drug antibody incidence was 5% (2 of 40), no injection site reactions occurred, mean half-life ranged from 55.0 to 65.8 days, and exposure increased in a near dose-proportional manner from 20 to 900 mg.
Result source: NCT05790694
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Sunakiment | WIN378 |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | —Not reported | —Not reported |
| ACQ-5, change | —Not reported | —Not reported |
| OCS dose reduction | —Not reported | —Not reported |
Severe exacerbations, annualised rate
- Sunakiment
- —Not reported
- WIN378
- —Not reported
Trough FEV1, change
- Sunakiment
- —Not reported
- WIN378
- —Not reported
ACQ-5, change
- Sunakiment
- —Not reported
- WIN378
- —Not reported
OCS dose reduction
- Sunakiment
- —Not reported
- WIN378
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Sunakiment: no structured comparison results are available for Asthma.
WIN378: no structured comparison results are available for Asthma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sunakiment's landscape · WIN378's landscape